The strengths of our study includes liver-biopsy proven NAFLD patients with long-term outcome data, an unbiased analysis of gene expression, and the use of DNA methylation data to corroborate the gene expression association we found with BCAT1. Our study also has several limitations. The gene discussed is BCAT1; the disease is metabolic dysfunction-associated steatotic liver disease.